Saracatinib in Treating Patients With Relapsed or Refractory Thymoma or Thymic Cancer
Status:
Terminated
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well saracatinib works in treating patients with relapsed
or refractory thymoma or thymic cancer. Saracatinib may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth